The successful treatment experience of BV has laid the foundation for the development of novel anti-CD30 therapies, which mainly include chimeric antigen receptor T (CAR-T) cells and bispecific antibodies. This evidence concerns the gene TNFRSF8 and bacterial vaginosis.